SCHEMBL3015982

SCHEMBL3015982

O=S(=O)(c1ccc(F)cc1)C1CCN(c2nc(Cc3ccccc3)cs2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 8/20 0.44
KCNH2 Q12809 6/20 0.44
HTR2C P28335 5/20 0.44
SMN1; SMN2 Q16637 5/20 0.42
L3MBTL1 Q9Y468 3/20 0.42
ALDH1A1 P00352 2/20 0.42
DRD2 P14416 2/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 3/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GBA1 P04062 1/20 0.39
GPR6 P46095 1/20 0.38
MAPK1 P28482 2/20 0.38
ALOX5 P09917 1/20 0.38
MEN1 O00255 2/20 0.37
LMNA P02545 2/20 0.37
KMT2A Q03164 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3021897 0.90 HTR2A (0.45) HTR2AKCNH2HTR2CSMN1; SMN2L3MBTL1
SCHEMBL3022765 0.90 GBA1 (0.42) HTR2AKCNH2HTR2CSMN1; SMN2L3MBTL1
SCHEMBL3010872 0.90 SMN1; SMN2 (0.41) HTR2AKCNH2HTR2CSMN1; SMN2L3MBTL1
SCHEMBL3014724 0.90 HTR2A (0.46) HTR2AKCNH2HTR2CDRD2NPC1
SCHEMBL3012569 0.90 HTR2A (0.44) HTR2AKCNH2HTR2CSMN1; SMN2NPC1
SCHEMBL3020046 0.90 HTR2A (0.42) HTR2AKCNH2HTR2CSMN1; SMN2L3MBTL1
SCHEMBL3021758 0.90 GBA1 (0.49) HTR2AKCNH2HTR2CSMN1; SMN2ALDH1A1
SCHEMBL3017160 0.89 HTR2A (0.39) HTR2AKCNH2HTR2CSMN1; SMN2L3MBTL1
SCHEMBL3009945 0.89 GPR6 (0.42) HTR2AKCNH2HTR2CSMN1; SMN2L3MBTL1
SCHEMBL3009833 0.89 HTR2A (0.43) HTR2AKCNH2HTR2CSMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA HTR2A 752/4885KCNH2 3130/4885HTR2C 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.